PortalPublikationenPSMA PET predicts metastasis-free survival in the setting of...

PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy

Standard

PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. / Wenzel, Mike; Hussein, Rada; Maurer, Tobias; Karakiewicz, Pierre I; Tilki, Derya; Graefen, Markus; Würnschimmel, Christoph.

in: UROL ONCOL-SEMIN ORI, Jahrgang 40, Nr. 1, 01.2022, S. 7.e1-7.e8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wenzel, M, Hussein, R, Maurer, T, Karakiewicz, PI, Tilki, D, Graefen, M & Würnschimmel, C 2022, 'PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy', UROL ONCOL-SEMIN ORI, Jg. 40, Nr. 1, S. 7.e1-7.e8. https://doi.org/10.1016/j.urolonc.2021.06.008

APA

Wenzel, M., Hussein, R., Maurer, T., Karakiewicz, P. I., Tilki, D., Graefen, M., & Würnschimmel, C. (2022). PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. UROL ONCOL-SEMIN ORI, 40(1), 7.e1-7.e8. https://doi.org/10.1016/j.urolonc.2021.06.008

Vancouver

Wenzel M, Hussein R, Maurer T, Karakiewicz PI, Tilki D, Graefen M et al. PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. UROL ONCOL-SEMIN ORI. 2022 Jan;40(1):7.e1-7.e8. https://doi.org/10.1016/j.urolonc.2021.06.008

Bibtex

@article{7f1f849f5df145b8be5dc7080a80d54c,
title = "PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy",
abstract = "INTRODUCTION: To evaluate the impact of PSMA PET (prostate specific membrane antigen positron emission tomography) findings prior to salvage radiotherapy (SRT) in recurrent prostate cancer (PCa) after radical prostatectomy (RP) on metastasis-free survival (MFS).PATIENTS AND METHODS: Between 01/2012 and 12/2018, 1,599 patients received SRT for biochemical recurrence after RP at our institution. Five-year MFS of {"}positive PSMA PET{"} (n = 49) vs. {"}negative PSMA PET{"} (n = 106) vs. {"}no PSMA PET{"} (n = 1,599) prior to SRT was determined. For all time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied, with a significance threshold of P < 0.05. Further 4:1 propensity score matching for patient, cancer and treatment characteristics was performed to account for residual differences between groups.RESULTS: Of PSMA PET patients, 106 patients exhibited {"}negative PSMA PET{"} (68.4%) and 49 exhibited {"}positive PSMA PET{"} (31.6%). Median PSA at recurrence did not differ between groups (0.2 ng/ml; P= 0.4). After 4:1 propensity score matching, 5-year MFS between {"}no PSMA PET{"} and {"}negative PSMA PET{"} was 94.4 vs. 93.0%, respectively (P = 0.8). For {"}no PSMA PET{"} versus {"}positive PSMA PET{"}, 5-year MFS was significantly lower in {"}positive PSMA PET{"} (92.3 vs. 48.5%, respectively P < 0.0001). Finally, {"}positive PSMA PET{"} was independently associated with worse MFS compared to {"}no PSMA PET{"} after multivariable adjustment in the overall cohort (HR 13.8, CI 7.5-25.2, P < 0.001).CONCLUSIONS: Locoregional positive PSMA PET findings in recurrent patients after RP are highly predictive of worse MFS in the setting of SRT.",
author = "Mike Wenzel and Rada Hussein and Tobias Maurer and Karakiewicz, {Pierre I} and Derya Tilki and Markus Graefen and Christoph W{\"u}rnschimmel",
note = "Copyright {\textcopyright} 2021 Elsevier Inc. All rights reserved.",
year = "2022",
month = jan,
doi = "10.1016/j.urolonc.2021.06.008",
language = "English",
volume = "40",
pages = "7.e1--7.e8",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy

AU - Wenzel, Mike

AU - Hussein, Rada

AU - Maurer, Tobias

AU - Karakiewicz, Pierre I

AU - Tilki, Derya

AU - Graefen, Markus

AU - Würnschimmel, Christoph

N1 - Copyright © 2021 Elsevier Inc. All rights reserved.

PY - 2022/1

Y1 - 2022/1

N2 - INTRODUCTION: To evaluate the impact of PSMA PET (prostate specific membrane antigen positron emission tomography) findings prior to salvage radiotherapy (SRT) in recurrent prostate cancer (PCa) after radical prostatectomy (RP) on metastasis-free survival (MFS).PATIENTS AND METHODS: Between 01/2012 and 12/2018, 1,599 patients received SRT for biochemical recurrence after RP at our institution. Five-year MFS of "positive PSMA PET" (n = 49) vs. "negative PSMA PET" (n = 106) vs. "no PSMA PET" (n = 1,599) prior to SRT was determined. For all time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied, with a significance threshold of P < 0.05. Further 4:1 propensity score matching for patient, cancer and treatment characteristics was performed to account for residual differences between groups.RESULTS: Of PSMA PET patients, 106 patients exhibited "negative PSMA PET" (68.4%) and 49 exhibited "positive PSMA PET" (31.6%). Median PSA at recurrence did not differ between groups (0.2 ng/ml; P= 0.4). After 4:1 propensity score matching, 5-year MFS between "no PSMA PET" and "negative PSMA PET" was 94.4 vs. 93.0%, respectively (P = 0.8). For "no PSMA PET" versus "positive PSMA PET", 5-year MFS was significantly lower in "positive PSMA PET" (92.3 vs. 48.5%, respectively P < 0.0001). Finally, "positive PSMA PET" was independently associated with worse MFS compared to "no PSMA PET" after multivariable adjustment in the overall cohort (HR 13.8, CI 7.5-25.2, P < 0.001).CONCLUSIONS: Locoregional positive PSMA PET findings in recurrent patients after RP are highly predictive of worse MFS in the setting of SRT.

AB - INTRODUCTION: To evaluate the impact of PSMA PET (prostate specific membrane antigen positron emission tomography) findings prior to salvage radiotherapy (SRT) in recurrent prostate cancer (PCa) after radical prostatectomy (RP) on metastasis-free survival (MFS).PATIENTS AND METHODS: Between 01/2012 and 12/2018, 1,599 patients received SRT for biochemical recurrence after RP at our institution. Five-year MFS of "positive PSMA PET" (n = 49) vs. "negative PSMA PET" (n = 106) vs. "no PSMA PET" (n = 1,599) prior to SRT was determined. For all time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied, with a significance threshold of P < 0.05. Further 4:1 propensity score matching for patient, cancer and treatment characteristics was performed to account for residual differences between groups.RESULTS: Of PSMA PET patients, 106 patients exhibited "negative PSMA PET" (68.4%) and 49 exhibited "positive PSMA PET" (31.6%). Median PSA at recurrence did not differ between groups (0.2 ng/ml; P= 0.4). After 4:1 propensity score matching, 5-year MFS between "no PSMA PET" and "negative PSMA PET" was 94.4 vs. 93.0%, respectively (P = 0.8). For "no PSMA PET" versus "positive PSMA PET", 5-year MFS was significantly lower in "positive PSMA PET" (92.3 vs. 48.5%, respectively P < 0.0001). Finally, "positive PSMA PET" was independently associated with worse MFS compared to "no PSMA PET" after multivariable adjustment in the overall cohort (HR 13.8, CI 7.5-25.2, P < 0.001).CONCLUSIONS: Locoregional positive PSMA PET findings in recurrent patients after RP are highly predictive of worse MFS in the setting of SRT.

U2 - 10.1016/j.urolonc.2021.06.008

DO - 10.1016/j.urolonc.2021.06.008

M3 - SCORING: Journal article

C2 - 34340868

VL - 40

SP - 7.e1-7.e8

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 1

ER -